Compare Gold Fields Limited (GFI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Viatris Inc — how do they compare? Gold Fields Limited trades at $36.71 (market cap $31.87B), while Viatris Inc trades at $17.61 (market cap $20.03B). The key difference: Gold Fields Limited is the larger of the two by market cap, and Gold Fields Limited pays the higher dividend (6%). Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and Viatris Inc for 57 Days on average.
| GFI | VTRS | |
|---|---|---|
Market Cap | $31.87B | $20.03B |
Volume | 4,169,651 | 14,109,977 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $18.27 |
52-Week Low | $31.25 | $9.74 |
Typical Hold Time | 49 Days | 57 Days |
Enterprise Value | $32.47B | $32.15B |
Dividend Yield | 6% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $36.70, up 4.71% over 24 hours, but technical indicators signal a bearish trend with price near support at $35. The company reported strong 2025 results with revenue of $8.75 billion and net income of $3.57 billion, yielding high profitability margins. However, recent earnings misses and a rejected $27 billion takeover bid for Northern Star have introduced volatility. Analyst consensus remains positive with a $52.75 price target, but the stock faces headwinds from acquisition-related uncertainty and mixed technical signals.
GFI presents a compelling value case with low P/E of 7.3 and robust cash flow growth, but investors must weigh execution risks from its aggressive M&A strategy and recent earnings inconsistencies against its strong fundamentals and shareholder returns. The stock's near-term direction hinges on merger outcomes and gold price stability.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
